Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| QGAI | NT 10-K | bearish | 6/10 | 🔒Quantum Genesis AI Corp. filed a Notification of Late Filing (NT 10-K) for its annual report for the fiscal year ended J | Oct 27, 2026 |
| ICLR | 6-K | bearish | 5/10 | 🔒ICON plc filed its Q3 2026 6-K, reporting a 2.9% YoY revenue decline to $2.02B and net income of $122.1M, a sharp improv | Oct 27, 2026 |
| VNRX | 8-K | neutral | 4/10 | 🔒VolitionRx prepaid $500,000 in cash on its $2.4M convertible note to Lind Global, reducing outstanding principal to $706 | Oct 27, 2026 |
| DARE | DEFA14A | bearish | 6/10 | 🔒Dare Bioscience filed additional definitive proxy soliciting materials (DEFA14A) reminding stockholders to vote ahead of | Oct 27, 2026 |
| CDT | DEF 14A | bearish | 6/10 | 🔒CDT Equity Inc. is holding a virtual special meeting on November 12, 2026 to seek stockholder approval for (1) the issua | Oct 27, 2026 |
| RAPP | 424B5 | neutral | 3/10 | 🔒Rapport Therapeutics filed a preliminary prospectus supplement for an offering of convertible senior notes due 2032, wit | Oct 27, 2026 |
| RAPP | 424B5 | bearish | 5/10 | 🔒Rapport Therapeutics filed a preliminary prospectus supplement for an underwritten public offering of common stock, with | Oct 27, 2026 |
| CRDF | 3 | neutral | 1/10 | 🔒Leila Alland filed a Form 3 initial statement of beneficial ownership upon becoming Chief Medical Officer of Cardiff Onc | Oct 27, 2026 |
| ICLR | 6-K | bearish | 5/10 | 🔒ICON reported Q3 2026 revenue of $2,024.8 million, down 2.9% YoY, and adjusted diluted EPS of $2.66, down from $3.20 YoY | Oct 27, 2026 |
| CRDF | 8-K | neutral | 4/10 | 🔒Cardiff Oncology filed an 8-K reporting the departure of CMO Dr. Roger Sidhu and the appointment of Dr. Leila Alland as | Oct 27, 2026 |
| LLY | COURT-RULING | neutral | 3/10 | 🔒Novo Nordisk sought a preliminary injunction against Eli Lilly over comparative advertising for Zepbound and Mounjaro, a | Oct 27, 2026 |
| NVO | COURT-RULING | neutral | 4/10 | 🔒Novo Nordisk sought a preliminary injunction to stop Eli Lilly's comparative advertising for Zepbound and Mounjaro, argu | Oct 27, 2026 |
| IRD | CLUSTER | neutral | 2/10 | 🔒Three insiders at Opus Genetics (IRD) sold a total of $174K in open-market sales on October 23, 2026. The CEO and Presid | Oct 27, 2026 |
| SNTI | 8-K | neutral | 4/10 | 🔒Board member Edward Mathers resigned effective immediately, and the company set a record date of October 30, 2026 for th | Oct 27, 2026 |
| RAPP | PRESS-RELEASE | bearish | 6/10 | 🔒Rapport Therapeutics announced separate underwritten public offerings of $200M in common stock and $150M in convertible | Oct 27, 2026 |
| WVE | SC 13G | neutral | 4/10 | 🔒BlackRock filed a Schedule 13G disclosing a 6.8% passive stake in Wave Life Sciences as of September 30, 2026, represent | Oct 27, 2026 |
| AYTU | DEFA14A | neutral | 2/10 | 🔒Aytu BioPharma filed additional definitive proxy soliciting materials (DEFA14A) on October 27, 2026, five days after its | Oct 27, 2026 |
| TELO | S-3 | neutral | 4/10 | 🔒Telomir Pharmaceuticals filed an S-3 registration statement to register 5,292,810 shares for resale by selling securityh | Oct 27, 2026 |
| CDT | SC 13D/A | neutral | 4/10 | 🔒Corvus Capital Ltd., Manoira Corporation, and Dr. Andrew Regan filed Amendment No. 7 to their Schedule 13D, disclosing a | Oct 27, 2026 |
| CDT | 3 | neutral | 2/10 | 🔒Manoira Corp filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing it is a 10%+ owner of CDT | Oct 27, 2026 |
| FF | PRESS-RELEASE, 8-K | neutral | 2/10 | 🔒FutureFuel Corp. filed an 8-K announcing it will release Q3 2026 financial results after market close on November 9, 202 | Oct 27, 2026 |
| FTH | 3 | neutral | 2/10 | 🔒Adam Schayowitz filed a Form 3 initial statement of beneficial ownership with the SEC, indicating he has become an offic | Oct 27, 2026 |
| SLGL | SC 13G | neutral | 3/10 | 🔒Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai filed a Schedule 13G disc | Oct 27, 2026 |
| KROS | SC 13G/A | neutral | 3/10 | 🔒BlackRock Portfolio Management LLC filed an amended Schedule 13G disclosing a 9.1% passive stake in Keros Therapeutics a | Oct 27, 2026 |
| VNDA | SC 13G | neutral | 4/10 | 🔒BlackRock Portfolio Management LLC filed a Schedule 13G disclosing a 5.9% passive stake in Vanda Pharmaceuticals as of S | Oct 27, 2026 |
| MYGN | SC 13G/A | neutral | 2/10 | 🔒BlackRock Portfolio Management LLC filed an amended Schedule 13G for Myriad Genetics Inc, reporting beneficial ownership | Oct 27, 2026 |
| ENTA | SC 13G | neutral | 4/10 | 🔒BlackRock Portfolio Management LLC filed a new Schedule 13G disclosing a 5.4% passive stake in Enanta Pharmaceuticals, r | Oct 27, 2026 |
| FULC | SC 13G/A | neutral | 3/10 | 🔒BlackRock Portfolio Management LLC filed an amended Schedule 13G disclosing a 8.1% passive stake in Fulcrum Therapeutics | Oct 27, 2026 |
| DWTX | SC 13D/A | neutral | 3/10 | 🔒Sealbond Ltd, the controlling shareholder of Dogwood Therapeutics, filed Amendment No. 4 to its Schedule 13D, reporting | Oct 27, 2026 |
| NRC | 8-K | neutral | 5/10 | 🔒NRC Health reported Q3 2026 revenue of $38.4M, up 11% YoY, and GAAP/Adjusted EPS of $0.21, in line with the consensus es | Oct 27, 2026 |